Projecting future drug expenditures—2005
Open Access
- 15 January 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 62 (2) , 149-167
- https://doi.org/10.1093/ajhp/62.2.149
Abstract
Purpose. Drug expenditure trends in 2003 and 2004 and projected drug expenditures for 2005 are discussed. Summary. Various factors are likely to affect drug costs, including drug prices, drugs in development, and generic drugs. In 2003 there was a continued moderation of the increase in drug expenditures. Drug expenditures increased by 11.4% from 2002 to 2003. Through the first nine months of 2004, expenditures increased by only 8.7% compared with 2003. This moderation can be attributed to many factors, particularly patent expirations, prescription-to-nonprescription conversions, and a continued slowdown in new drug approvals. Higher cost sharing for consumers and continued weaknesses in several sectors of the U.S. economy affecting employment levels and insurance coverage also contributed to this smaller increase in drug utilization. It is expected that 2005 drug expenditure growth will outpace the growth in overall health care expenditures and growth in the economy. Conclusion. In 2005, there should be a 10–12% increase in drug expenditures in outpatient settings, a 12–15% increase in clinics, and a 6–9% increase in hospitals.Keywords
This publication has 42 references indexed in Scilit:
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Mid-year at the FDA highlights permanent problemNature Reviews Drug Discovery, 2004
- Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life‐threatening bleedingVox Sanguinis, 2004
- CetuximabNature Reviews Drug Discovery, 2004
- Betting on biogenericsNature Reviews Drug Discovery, 2004
- Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713Journal of Clinical Oncology, 2004
- 'New' FDA delivers in 2003Nature Reviews Drug Discovery, 2003
- July highlightsAmerican Journal of Kidney Diseases, 2003
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Off-label use of recombinant factor VIIa in patients following bone marrow transplantationBone Marrow Transplantation, 2001